Twist Bioscience to Present at Upcoming Investor Conferences

Twist Bioscience Corporation (NASDAQ: TWST) announced key presentations by CEO Emily M. Leproust and CFO Jim Thorburn at upcoming investor conferences.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

02/28/2023 - 08:00 AM EST

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming investor conferences:

Cowen 43^rd Annual Healthcare Conference in Boston, MA;
- Fireside chat on Tuesday, March 7 at 1:30 p.m. Eastern Time.
- SynBio & AI Driven Drug Discovery Panel: Monday, March 6 at 4:40 p.m. Eastern Time.
- Synthetic Biology Enabling Tools Panel: Tuesday, March 7 at 4:40 p.m. Eastern Time.

Barclays Global Healthcare Conference on Tuesday, March 14 in Miami, FL; fireside chat at 2:05 p.m. Eastern Time.

The Cowen fireside chat and panels and Barclays fireside chat will be webcast live and can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company's website here. A replay of the fireside chats will be archived for a period of 30 days following the conclusion of the live events.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.